Prothena (PRTA) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued 12-month target prices for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they anticipate the company's stock price to reach $86.33 in the next year. This suggests a possible upside of 30.0% from the stock's current price.
View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts.

Prothena's stock was trading at $60.25 at the start of the year. Since then, PRTA stock has increased by 10.2% and is now trading at $66.39.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our PRTA earnings forecast.

Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by $0.06. The biotechnology company earned $2.17 million during the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative net margin of 232.19% and a negative trailing twelve-month return on equity of 24.99%. The business's quarterly revenue was up 88.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.78) earnings per share.

ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Prothena's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (12.82%), BlackRock Inc. (6.87%), Price T Rowe Associates Inc. MD (6.07%), Wellington Management Group LLP (4.30%), State Street Corp (3.99%) and Palo Alto Investors LP (3.15%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago.
View institutional ownership trends.

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRTA stock can currently be purchased for approximately $66.39.

Prothena (NASDAQ:PRTA) has a market capitalization of $3.50 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.